OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.440
-0.020 (-1.37%)
At close: Jun 5, 2026, 4:00 PM EDT
1.460
+0.020 (1.39%)
After-hours: Jun 5, 2026, 7:47 PM EDT
OPKO Health Revenue
OPKO Health had revenue of $124.20M in the quarter ending March 31, 2026, a decrease of -17.18%. This brings the company's revenue in the last twelve months to $432.67M, down -37.24% year-over-year. In the year 2025, OPKO Health had annual revenue of $606.90M, down -14.90%.
Revenue (ttm)
$432.67M
Revenue Growth
-37.24%
P/S Ratio
1.87
Revenue / Employee
$255,439
Employees
2,275
Market Cap
1.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 606.90M | -106.24M | -14.90% |
| Dec 31, 2024 | 713.14M | -150.35M | -17.41% |
| Dec 31, 2023 | 863.50M | -140.71M | -14.01% |
| Dec 31, 2022 | 1.00B | -770.52M | -43.42% |
| Dec 31, 2021 | 1.77B | 339.31M | 23.64% |
| Dec 31, 2020 | 1.44B | 533.48M | 59.15% |
| Dec 31, 2019 | 901.94M | -88.33M | -8.92% |
| Dec 31, 2018 | 990.27M | 24.26M | 2.51% |
| Dec 31, 2017 | 966.01M | -151.48M | -13.56% |
| Dec 31, 2016 | 1.12B | 625.75M | 127.25% |
| Dec 31, 2015 | 491.74M | 400.61M | 439.63% |
| Dec 31, 2014 | 91.13M | -5.41M | -5.60% |
| Dec 31, 2013 | 96.53M | 49.49M | 105.19% |
| Dec 31, 2012 | 47.04M | 19.07M | 68.14% |
| Dec 31, 2011 | 27.98M | -515.00K | -1.81% |
| Dec 31, 2010 | 28.49M | 24.08M | 544.95% |
| Dec 31, 2009 | 4.42M | -5.02M | -53.20% |
| Dec 31, 2008 | 9.44M | 8.59M | 1,014.52% |
| Dec 31, 2007 | 847.00K | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| NeoGenomics | 745.97M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
| Adaptive Biotechnologies | 295.41M |
OPK News
- 3 days ago - OPKO Health Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 22 days ago - OPKO Health Proxy statement: Proxy filing - Filings
- 25 days ago - OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies - GlobeNewsWire
- 4 weeks ago - OPKO Health Slides: Corporate presentation - Filings
- 5 weeks ago - OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - GlobeNewsWire
- 5 weeks ago - BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - GlobeNewsWire
- 5 weeks ago - OPKO Health Proxy statement: Proxy filing - Filings
- 5 weeks ago - OPKO Health Proxy statement: Proxy filing - Filings